Literature DB >> 29146181

Proximity labeling of cis-ligands of CD22/Siglec-2 reveals stepwise α2,6 sialic acid-dependent and -independent interactions.

Amin Alborzian Deh Sheikh1, Chizuru Akatsu1, Akihiro Imamura2, Hajjaj H M Abdu-Allah2, Hiromu Takematsu3, Hiromune Ando4, Hideharu Ishida5, Takeshi Tsubata6.   

Abstract

Lectins expressed on the cell surface are often bound and regulated by the membrane molecules containing the glycan ligands on the same cell (cis-ligands). However, molecular nature and function of cis-ligands are generally poorly understood partly because of weak interaction between lectins and glycan ligands. Cis-ligands are most extensively studied in CD22 (also known as Siglec-2), an inhibitory B lymphocyte receptor specifically recognizing α2,6 sialic acids. CD22, CD45 and IgM are suggested to be ligands of CD22. Here we labeled molecules in the proximity of CD22 in situ on B cell surface using biotin-tyramide. Molecules including CD22, CD45 and IgM were labeled in wild-type but not ST6GalI-/- B cells that lack α2,6 sialic acids, indicating that these molecules associate with CD22 by lectin-glycan interaction, and are therefore cis-ligands. In ST6GalI-/- B cells, these cis-ligands are located in a slightly more distance from CD22. Thus, the lectin-glycan interaction recruits cis-ligands already located in the relative proximity of CD22 through non-lectin-glycan interaction to the close proximity. Moreover, cis-ligands are labeled in Cmah-/- B cells that lack Neu5Gc preferred by mouse CD22 as efficiently as in wild-type B cells, indicating that very low affinity lectin-glycan interaction is sufficient for recruiting cis-ligands, and can be detected by proximity labeling. Thus, proximity labeling with tyramide appears to be a useful method to identify cis-ligands and to analyze their interaction with the lectins.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD22; Cis-ligands; Proximity labeling; Sialic acids

Mesh:

Substances:

Year:  2017        PMID: 29146181     DOI: 10.1016/j.bbrc.2017.11.086

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Rituximab mechanisms of action in B-CLL: a new piece of the puzzle.

Authors:  Hervé Watier
Journal:  Oncotarget       Date:  2018-08-28

Review 2.  B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.

Authors:  Sarah J Meyer; Alexandra T Linder; Carolin Brandl; Lars Nitschke
Journal:  Front Immunol       Date:  2018-12-03       Impact factor: 7.561

Review 3.  Siglec Ligands.

Authors:  Anabel Gonzalez-Gil; Ronald L Schnaar
Journal:  Cells       Date:  2021-05-20       Impact factor: 6.600

4.  CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.

Authors:  Naoko Matsubara; Akihiro Imamura; Tatsuya Yonemizu; Chizuru Akatsu; Hongrui Yang; Akiharu Ueki; Natsuki Watanabe; Hajjaj Abdu-Allah; Nobutaka Numoto; Hiromu Takematsu; Shinobu Kitazume; Thomas F Tedder; Jamey D Marth; Nobutoshi Ito; Hiromune Ando; Hideharu Ishida; Makoto Kiso; Takeshi Tsubata
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

Review 5.  Ligand Recognition Determines the Role of Inhibitory B Cell Co-receptors in the Regulation of B Cell Homeostasis and Autoimmunity.

Authors:  Takeshi Tsubata
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

6.  Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus.

Authors:  Patricia A Blundell; Dongli Lu; Mark Wilkinson; Anne Dell; Stuart Haslam; Richard J Pleass
Journal:  J Immunol       Date:  2019-01-25       Impact factor: 5.422

Review 7.  Recent Progress in the Methodologies to Identify Physiological Ligands of Siglecs.

Authors:  Huei-Syuan Jiang; Shao-Chien Zhuang; Chak Hin Lam; Lan-Yi Chang; Takashi Angata
Journal:  Front Immunol       Date:  2021-12-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.